Document is current
Any future updates will be listed below
-
Authors
Parry, Matthew G. https://orcid.org/0000-0002-9695-6052
Nossiter, Julie https://orcid.org/0000-0002-8597-7624
Morris, Melanie
Sujenthiran, Arunan
Skolarus, Ted A.
Berry, Brendan https://orcid.org/0000-0001-7132-5839
Nathan, Arjun https://orcid.org/0000-0002-8572-2832
Cathcart, Paul
Aggarwal, Ajay
van der Meulen, Jan https://orcid.org/0000-0002-9451-2335
Trinh, Quoc-Dien
Payne, Heather https://orcid.org/0000-0003-3238-5040
Clarke, Noel W.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA242559, R37 CA222885)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 5 October 2021
Revised: 24 November 2021
Accepted: 26 November 2021
First Online: 10 January 2022
Competing interests
: AS is an employee of Flatiron Health, an independent subsidiary of the Roche group, and holds stock in Roche. JvdM reports a contract with the Healthcare Quality Improvement Partnership for the provision of the National Prostate Cancer Audit () funded by the Healthcare Quality Improvement Partnership (). HP has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Janssen, Sanofi Aventis, Takeda, Ipsen, Ferring, Sandoz, and Novartis. N.W.C. has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Bayer, Janssen, Sanofi Aventis, Takeda, Ipsen and Ferring.
: This study was exempt from NHS Research Ethics Committee approval because it involved analysis of pseudonymised linked data collated for the purpose of service evaluation as part of the National Prostate Cancer Audit.
